Pressure and Pain In Systemic Sclerosis/ Scleroderma PDF Print E-mail
Saturday, 18 February 2012 12:10
Begonya Alcacer-Pitarch, Maya H Buch, Janine Gray, Christopher P Denton, Ariane Herrick, Nuria Navarro-Coy, Howard Collier, Lorraine Loughrey, Sue Pavitt, Heidi J Siddle, Jonathan Wright, Philip S Helliwell, Paul Emery, Anthony C Redmond
Study protocol, Submitted 14 December 2011, Accepted 6 February 2012, Published 6 February 2012

Foot problems associated with Systemic Sclerosis (SSc)/Scleroderma have been reported to be both common and disabling. There are only limited data describing specifically, the mechanical changes occurring in the foot in SSc. A pilot project conducted in preparation for this trial confirmed the previous reports of foot related impairment and reduced foot function in people with SSc and demonstrated a link to mechanical etiologies. To-date there have been no formal studies of interventions directed at the foot problems experienced by people with Systemic Sclerosis. The primary aim of this trial is to evaluate whether foot pain and footrelated health status in people with Systemic Sclerosis can be improved through the provision of a simple pressure-relieving insole.

The proposed trial is a pragmatic, multicenter, randomised controlled clinical trial following a completed pilot study. In four participating centres, 140 consenting patients with SSc and plantar foot pain will be randomised to receive either a commercially available pressure relieving and thermally insulating insole, or a sham insole with no cushioning or thermal properties. The primary end point is a reduction in pain measured using the Foot Function Index Pain subscale, 12 weeks after the start of intervention. Participants will complete the primary outcome measure (Foot Function Index pain sub-scale) prior to randomisation and at 12 weeks post randomisation. Secondary outcomes include participant reported pain and disability as derived from the Manchester Foot Pain and Disability Questionnaire and plantar pressures with and without the insoles in situ.

Continue reading the full study protocol, by downloading it from the link provided below.

 
More articles :

» Diagnosis, Management and Prevention of Scleroderma Renal Disease

Henry Penn; Christopher P. DentonPosted: 11/14/2008; Curr Opin Rheumatol. 2008;20(6):692-696. © 2008 Lippincott Williams & WilkinsPurpose of Review: Renal complications are important in scleroderma (systemic sclerosis) and include scleroderma...

» Cancer Drug Shows Promise For Treating Scleroderma

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with , according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold...

» Coping With Scleroderma

Coping with SclerodermaBy Jane Brandenstein, P.T., University of Pittsburgh Medical CenterAs physical therapists, there are some things that we have learned over the years about Scleroderma, and there are even more things we wish we understood...

» Dermatomyositis

Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness. Dermatomyositis’ cardinal symptom is a skin rash that precedes or...

» U.S. Legislation Passed to Promote Research and Awareness of Scleroderma

(U.S.) has applauded the U.S. House of Representatives for the passage of the Scleroderma Research and Awareness Act (H.R. 2408), introduced last March by Rep. Lois Capps (D-CA) and Rep. Vern Ehlers (R-MI). This bipartisan legislation gives hope to...

» Immunosuppressive Medications During Pregnancy and Lactation In Women with Autoimmune Diseases

Amy B Elliott & Eliza F Chakravarty10.2217/WHE.10.24 © 2010 Future Medicine LtdWomen's Health (2010) 6(3), 431–442Most autoimmune diseases predominantly affect females. Many of these diseases occur in women who have the potential to become...